South Korea’s two leading biopharmaceutical companies, Samsung Biologics and Celltrion, unveiled ambitious plans to enter the ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ...

Additionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...

Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.

Transforming the landscape of drug discovery with next-gen capabilities in obesity research, small molecule and antibody design, antibody-drug conjugate development, and interactive AI AlpaMeld Logo ...

Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025(Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific anti ...

Biohaven Ltd.(NYSE: BHVN) and  Merus N.V.(Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging ...

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.